ERBB2 and neoplasm: Furthermore, a recent prospective observational study demonstrated promising anti-tumor effects in patients with HER2-positive and Ras wild-type mCRC following treatment with either Pyrotinib alone or in combination with trastuzumab (Zhou et al., 2024).